Navigation Links
DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology
Date:7/8/2009

degradation.

DOR anticipates proceeding towards clinical development of an oral form of the peptide hormone drug leuprolide using the LPM(TM) technology. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone (GnRh) that is used in treatment of endometriosis in women and prostate cancer in men. In preclinical studies in rats and dogs, DOR has demonstrated that the LPM(TM) technology results in high systemic bioavailability of intestinally absorbed leuprolide. In both animal models, the bioavailability of leuprolide ranged from 20 to 40 percent, compared to 2.2 percent for the control oral solution. Leuprolide is one of the most widely used anti-cancer agents for advanced prostate cancer in men. Injectable forms of leuprolide marketed under tradenames such as Lupron(R) and Eligard(R) had worldwide sales of approximately $1.8 billion in 2006. Injectable leuprolide is also widely used in non-cancer indications, such as endometriosis in women (a common condition in which cells normally found in the uterus become implanted in other areas of the body), uterine fibroids in women (noncancerous growths in the uterus) and central precocious puberty in children (a condition causing children to enter puberty too soon). Leuprolide is currently available only in injectable, injectable depot and subcutaneous implant routes of delivery.

LPM(TM) is thought to promote intestinal absorption through the action of the micelles to open up small channels that allow only molecules of a certain dimension to pass through, excluding extremely large molecules, bacteria and viruses. The reverse micelles also structurally prevent the rapid inactivation of peptides by enzymes in the upper gastrointestinal tract. Other sensitive drugs that can be delivered orally with the LPM(TM) system include various classes of drugs such as peptides, nucleic acids and proteins which are degraded in the stomach and small intestine. Corresponding patents in
'/>"/>

SOURCE DOR BioPharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Morphotek(R), Inc. Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and Infectious Disease
2. DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation
3. Gyros Raises SEK 80 Million to Accelerate the Commercialization of its Gyrolab(R) Systems for the Cost-Efficient Development of Biopharmaceuticals
4. KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
5. Helix BioPharma to Present L-DOS47 Analytical Method Development Findings at 2009 AAPS National Biotechnology Conference
6. Lytix Biopharma and KAEL-GemVax Announce Joint Clinical Trial to Combine LTX-315 and GV1001 Cancer Immunotherapy
7. Wound Management Technologies, Inc. Announced Today That It Has Reached an Agreement in Principal to Acquire BioPharma Management Technologies, Inc.
8. Helix BioPharma Announces Q3 2009 Financial Results and Provides Product Development Update
9. PDL BioPharma Provides Second Quarter 2009 Revenue Guidance of Approximately $125 Million
10. Keryx Biopharmaceuticals Reports Positive Phase 2 Study Results of Zerenex (Ferric Citrate) for the Treatment of Hyperphosphatemia in End-Stage Renal Disease Patients
11. Sinobiopharma Applies For Two Chinese Patents For Cisatracurium Besylate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/10/2009)... Dec. 10 Microban International, Ltd., ... protection, has partnered with Sharp Imaging and ... Sharp Electronics, to incorporate it,s third generation ... calculators. Infused into the calculator keys during ... the growth of damaging bacteria on the ...
(Date:12/10/2009)... division of the National Institutes of Health (NIH), awarded a ... development of a non-invasive, passive diffusion-based treatment for severe, non-infectious ... ... Lake City, UT (PRWEB) December 10, 2009 -- The National ... Health (NIH), awarded a $2.18 million grant to Aciont Inc. ...
(Date:12/10/2009)... 10 Newly published research, by ... Cell Institute (NESCI) in the journal STEM ... eight patients with "Limbal Stem Cell Deficiency" ... without the need of suppressing their immunity. ... LSCD is a painful, blinding disease that ...
(Date:12/10/2009)... advanced flow measurement, control, and level solutions, announced ... Global Level Product Manager effective November 30, 2009. ... market penetration of the level measurement products around ... Lafarge Corp, a manufacturer of building materials, where ... Bayda will report to Brooks Instrument Vice President ...
Breaking Biology Technology:Microban Signs Exclusive Agreement with Sharp Electronics to Launch Calculators with New Microban(R) 3G Silver(TM) Antimicrobial Technology 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 2NEI Awards a Two-Year $2.18 Million SBIR Grant to Aciont 3Successful Stem Cell Therapy for Treatment of Eye Disease 2Successful Stem Cell Therapy for Treatment of Eye Disease 3Successful Stem Cell Therapy for Treatment of Eye Disease 4Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 2Brooks Instrument Appoints Mike Bayda as Global Level Product Manager 3
... Growth of 14% ... Fiscal 2009 Revenue Guidance, HOUSTON, June 11 Cyberonics, Inc. (Nasdaq:,CYBX) ... 2008., Key quarterly highlights, Key results for the fourth quarter ... -- Net sales of $33.9 million, an 8% increase from $31.4 ...
... (Nasdaq:,BIOD) today announced that Barry Ginsberg, M.D., Ph.D., has ... Directors, effective June 10, 2008. Dr.,Ginsberg is currently Chief ... 500 companies in the field of,diabetes., "We are ... at such an,important time for Biodel," stated Dr. Solomon ...
... - Oncothyreon Inc.,(Nasdaq: ONTY ) (TSX: ONY) ... been treated in a Phase 1b clinical trial ... is a proprietary small molecule,inhibitor of thioredoxin, a ... the growth, survival and drug resistance of,many cancers., ...
Other Biology Technology:Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 2Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 3Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 4Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 5Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 6Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 7Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 8Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 9Cyberonics Reports Strong Revenue Growth and Profitability in Fiscal 2008 Fourth Quarter 10Barry Ginsberg, M.D., Ph.D. Elected to Biodel's Board of Directors 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 2Oncothyreon initiates Phase 1b trial of PX-12 in patients with advanced metastatic cancer 3
(Date:12/14/2009)... The most comprehensive study to date of the proteins ... may provide important clues to how similar regeneration could ... School of Science at Indiana University-Purdue University Indianapolis and ... limbs of axolotls, a type of salamander that has ... level of amputation, with the hope that this knowledge ...
(Date:12/14/2009)... In support of the United Nations Framework Convention ... European Environment Agency hosted the ,Bend the Trend, ... climate networking platform and premiere the screening of ... ,Environmental Atlas of Europe, a joint project of ... Programme (UNEP) and ESA, is a series of ...
(Date:12/13/2009)... a question about how a popular class of ... that reveal previously hidden components of chemical communication ... hallucinations characterize the illness, people with schizophrenia also ... a particular order, difficulties that interfere with their ... said Lee Schroeder, a student in the medical ...
Breaking Biology News(10 mins):IUPUI researchers tackle protein mechanisms behind limb regeneration 2'Environmental Atlas of Europe' unveiled at COP15 2New biosensors reveal workings of anti-psychotic drugs in the living brain 2Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 1Atlantic Pharmaceuticals Inc Announces Completion of Successful Pre IND Meeting with FDA for Abuse Deterrent Narcotic 49728 2NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 1NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 2NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 3NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 4NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 5NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 6NUCYNTA 28TM 29 28tapentadol 29 CII Immediate Release Tablets Now Available for Relief of Moderate to Severe Acute Pain 49726 7Electronic Medical Record Technology Uptake Faces Challenges 49724 1Electronic Medical Record Technology Uptake Faces Challenges 49724 2
... BIO-key International,Inc. (OTC Bulletin Board: BKYI), a ... solutions, today announced that it,has been awarded a ... a large multi-national technology company. BIO-key will,license components ... used on,multiple, large international and domestic opportunities., ...
... TAMPA, Fla., June 2 Stinger Systems, Inc.,(OTC ... today,announced that the Canyon County Sheriff,s Office (CCSO) ... Device. CCSO is a,329-man department., Lt. Daren ... other EID product,and was seeking alternatives that would ...
... understanding how environmental processes and agricultural practices interact ... chemicals in the environment is essential for effectively ... waters from past, present, and future agricultural activities. ... or smaller scales, the holistic understanding of processes ...
Other Biology News:BIO-key(R) Awarded $2 Million Biometric Contract by Multi-National Company 2Canyon County Idaho Sheriff's Office to Purchase Stinger S-200s 2Holistic understanding: Ag chemicals in the environment 2
Request Info...
... Electroporator is a simple, easy to ... in bacterial and yeast applications. ... two voltages and either one mm, ... On pressing the pulse button the ...
Request Info...
The Cellject Elecroporator is suitable for all cell types including embryo, mammalian, plant, yeast and bacterial. Its has highly user-freindly programing and can be used remotely, for example in a l...
Biology Products: